Zopapogene Imadenovec-drba Treatment for Adults With Recurrent Respiratory Papillomatosis: A Review

Importance After the US Food and Drug Administration approval of zopapogene imadenovec-drba and its recommendation as the first-line treatment for recurrent respiratory papillomatosis (RRP) in the RRP Foundation Position Statement, standard-of-care treatment for adults with RRP is changing. Practical questions arise with real-world implementation for any new treatment previously studied only in clinical trials. This Narrative Review aims to provide additional information beyond what is published in clinical trial reports to help otolaryngologists and medical oncologists consider how to implement zopapogene imadenovec-drba in their RRP practices. Observations In the pivotal phase 1/2 nonrandomized clinical trial, 51% of patients (18 of 35) achieved a complete response, defined as no clinically indicated surgical procedure received in the 12 months after treatment. This review provides further key information underlying the rationale behind the zopapogene imadenovec-drba pivotal trial design and considerations for clinical implementation and in specific populations. Conclusions and Relevance Zopapogene imadenovec-drba represents a novel immunotherapeutic approach designed to induce targeted durable disease control in adult RRP. This review provides practical guidance on patient selection, treatment administration, and perioperative management to support the clinical integration of nonsurgical management into routine otolaryngology and medical oncology practice.

Authors

Institutions

Publication Details

Journal
JAMA Otolaryngology–Head & Neck Surgery
Published
2026-11-19
DOI
https://doi.org/10.1001/jamaoto.2026.3674
Primary Topic
Head and Neck Cancer Studies
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Zopapogene Imadenovec-drba Treatment for Adults With Recurrent Respiratory Papillomatosis: A Review

Stephanie Misono, Scott Michael Norberg, Clint Tanner Allen
JAMA Otolaryngology–Head & Neck Surgery
Head and Neck Cancer Studies
article

Zopapogene Imadenovec-drba Treatment for Adults With Recurrent Respiratory Papillomatosis: A Review

Stephanie Misono, Scott Michael Norberg, Clint Tanner Allen
article en

Abstract

Importance After the US Food and Drug Administration approval of zopapogene imadenovec-drba and its recommendation as the first-line treatment for recurrent respiratory papillomatosis (RRP) in the RRP Foundation Position Statement, standard-of-care treatment for adults with RRP is changing. Practical questions arise with real-world implementation for any new treatment previously studied only in clinical trials. This Narrative Review aims to provide additional information beyond what is published in clinical trial reports to help otolaryngologists and medical oncologists consider how to implement zopapogene imadenovec-drba in their RRP practices. Observations In the pivotal phase 1/2 nonrandomized clinical trial, 51% of patients (18 of 35) achieved a complete response, defined as no clinically indicated surgical procedure received in the 12 months after treatment. This review provides further key information underlying the rationale behind the zopapogene imadenovec-drba pivotal trial design and considerations for clinical implementation and in specific populations. Conclusions and Relevance Zopapogene imadenovec-drba represents a novel immunotherapeutic approach designed to induce targeted durable disease control in adult RRP. This review provides practical guidance on patient selection, treatment administration, and perioperative management to support the clinical integration of nonsurgical management into routine otolaryngology and medical oncology practice.

JAMA Otolaryngology–Head & Neck Surgery
National Institutes of Health (US), University of Minnesota (US), National Cancer Institute (US), Center for Cancer Research (US)
Head and Neck Cancer Studies
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon